Cardioplegic preparation

Abstract

The present invention relates to a cardioplegic preparation. According to a preferred embodiment of the invention, the preparation is made of two solutions, the first containing magnesium sulfate, potassium and xylitol, and the other containing procaine.

Claims

1. A dose of a cardioplegic preparation consisting essentially of: a solution A consisting essentially of: magnesium sulfate heptahydrate 3-5 g potassium chloride 0.1-1.0 g xylitol 1-10 g water to a final volume of solution A that is 95% of a final volume of said dose, and a solution B consisting essentially of: procaine hydrochloride 0.1-1.0 g water to a final volume of solution B that is 5% of the final volume of said dose, wherein the final volume of said dose is 100 ml, and wherein solution A is buffered with citric acid monohydrate to a pH of 5.5 to 7.0.

2. A dose of a cardioplegic preparation consisting essentially of: a solution A consisting essentially of: magnesium sulfate heptahydrate 4 g potassium chloride 0.746 g xylitol 4.5 g citric acid monohydrate 1.061 g and water to a final volume of solution A that is 95 ml of a final volume of said dose, and a solution B consisting essentially of: procaine hydrochloride 0.3 g and water to a final volume of solution B that is 5 ml of the final volume of said dose.

Description

DESCRIPTION OF THE INVENTION

(1) The invention relates to a cardioplegic preparation containing at least magnesium and potassium.

(2) Advantageously the preparation is initially made of two separate solutions, the first containing said magnesium component and the second containing a local anesthetics, e.g. procaine.

(3) In a preferred embodiment the two solutions are containing the following components: Solution A: Magnesium Potassium Xylitol Solution B: Procaine

(4) The solutions are buffered so that the pH after mixture of both solutions is between 5.5 and 7.0

(5) Advantageously the following molecules are used: Solution A: Magnesium sulfate heptahydrate Potassium chloride Xylitol Solution B: Procaine hydrochloride

(6) Variations can include the following added component: Adenosine

(7) Variations can also use: Instead of Procaine, xylocain and/or Novocain and/or any other local anesthetics compatible with the components used in the preparation Instead of Xylitol, Manitol and/or any sugar compatible with the other components used in the preparation Magnesium chloride instead of Magnesium sulfate

(8) For one dose, the following ranges of quantities are advantageously used:

(9) TABLE-US-00001 Solution A: Magnesium sulfate heptahydrate .sup.  3-5 g Potassium chloride 0.1-1.0 g Xylitol .sup.  1-10 g Solution B: Procaine hydrochloride 0.1-1.0 g

(10) Water is used to have a final volume (solution A+solution B) of 20 to 250 ml.

(11) Solution A is buffered with citric acid monohydrate to a pH of 5.5 to 7.0.

(12) The following preparation is preferably used:

(13) TABLE-US-00002 Solution A: Magnesium sulfate heptahydrate .sup. 4 g 16.2 mmol Potassium chloride 0.746 g  10.0 mmol Xylitol 4.5 g 29.6 mmol Citric acid monohydrate 1.061 g   5.0 mmol Water for injection to a final volume of 95 ml Solution B: Procaine hydrochloride 0.3 g  1.1 mmol Water for injection to a final volume of 5 ml

(14) pH of the mixed ready to use solution is 6.0.

(15) The preparation is hyperosmolar with an osmolarity of the mixed ready to use solution of approximately 850 mosmol/l.

Pharmacological Tests

(16) Several pharmacologic tests have been performed and lead to the preparation according to the invention. After several unsuccessful attempts it became possible to obtain a preparation that is stable and sterile over several months. In addition, the preparation according to the invention offers the advantage of avoiding the known incompatibility between procaine and sulfate Importantly, the tests have also demonstrated that at 2-8° C. and within the first 60 minutes following the mixing of solutions A and B, this incompatibility is not relevant.

(17) As compared to previous cardioplegic solutions the preparation according to the invention has a higher potassium concentration. Experimental and clinical tests have both confirmed a reduced bioavailability of Potassium ions when in presence of xylitol and/or citric acid. By increasing thus the initial content of potassium in the cardioplegic solution, the concentration necessary to achieve the cardioplegic effect is guaranteed. In addition, clinical tests have confirmed that no potassium overdose is achieved.

(18) As compared to previous cardioplegic solutions pH is also reduced to 6.0 which interestingly and advantageously allows to increase the effect of procaine.

Production

(19) Solution A is prepared in a sterile way and stored in a vial with 95 ml. Solution B is also prepared in a sterile way and separately stored in a light protected 5 ml syringe.

Surgical Environment

(20) At least 3-4 hours before the surgical procedure, the solutions are stored at 2-8° C. The ready to use solution (100 ml) is obtained by injecting the content of the syringe (solution B, 5 ml) into the vial (solution A, 95 ml). This resulting mixture is administered within 60 minutes after mixing, preferably within 15 minutes after mixing.

Clinical Tests

(21) The preparation according to the invention was tested in several patients. The combination of the compounds was even tested in more than 3,000 patients and showed clear advantages as compared to traditional cardioplegic solutions. Not only the administration is simplified, but the cardiac arrest is almost instantaneous allowing thus the surgeon to immediately focus on his surgical procedure. Indeed, in most other cardioplegic strategies, the surgeon has to deliver a much larger quantity of solution and wait up to 5 minutes until the heart is considered ready to be operated on. Additionally, the current solution allows arrest and protection usually for more than 45-60 minutes whereas other solutions traditionally need to be repeated every 20 minutes. Clinical results are significantly superior since several of the post-operative complications can be reduced such as the rate of post-operative cardiac arythmias. More importantly, the preparation according to the invention can be integrated in the concept of new extra corporeal circulation (ECC) machines which aim to reduce or eliminate the trauma of such devices. This was recently confirmed in one study which showed in particular a significant reduction of post-ECC inflammatory reactions. A significant reduction of post-operative level of cardiac enzymes was observed. This confirms a better myocardial protection.

Advantages Provided by the Invention

(22) As compared to other state of the art cardioplegic solutions, the cardioplegic preparation according to the invention presents several significant advantages, in particular: 1. The presentation with two separated solutions allows to prevent the consequences of the known incompatibility between sulfate and procain. 2. Mixing the two solutions at 2 to 8° C. allows to prevent abnormal formation of microparticles within at least one hour. 3. Production can be performed at room temperature before sterilization. Both solutions can then be considered stable for more than 9 months at room temperature. This can be considered a significant advantage since production can be amplified and products can be stocked and the entire logistics is facilitated. 4. Immediate injection of the freshly mixed preparation in the coronary arteries allows immediate cardiac arrest. 5. Because the solution is concentrated in a low volume (only 100 ml), hemodilution is prevented. 6. Cardioplegic effect is prolonged and usually maintained for of at least 60 minutes. 7. Administration is simplified since the preparation can be directly and rapidly injected into the aorta by the surgeon himself. 8. The preparation is particularly adapted for coronary artery bypass operations. Several studies have been performed in hospitals. They included thousands of patients. They all confirmed that a significantly better myocardial protection can be achieved. Indeed, the experience shows that the level of post-operative cardiac enzymes, in other words markers of cardiac cellular lesions, is reduced as compared to other cardioplegic solutions.